• LAST PRICE
    1.4450
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.3500/ 13
  • Ask / Lots
    1.4800/ 90
  • Open / Previous Close
    0.0000 / 1.4450
  • Day Range
    ---
  • 52 Week Range
    Low 1.0400
    High 3.8800
  • Volume
    1
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeNNVC
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNNVC
NanoViricides Inc
16.8M
-2.4x
---
United StatesBPTH
Bio Path Holdings Inc
16.7M
-1.1x
---
United StatesBLPH
Bellerophon Therapeutics Inc
16.5M
-0.9x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
17.1M
-0.8x
---
United StatesRAPH
Raphael Pharmaceutical Inc
17.2M
-5.4x
---
United StatesTOVX
Theriva Biologics Inc
17.3M
-0.8x
---
As of 2023-02-08

Company Information

NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash. The Company also offers several additional pre-clinical drug development programs, including Herpes Simplex Viruses (HSV-1 that causes cold sores, and HSV-2 that causes genital ulcers), HIV/AIDS, Influenza, Dengue viruses, and Ebola/Marburg.

Contact Information

Headquarters
1 Controls DriveSHELTON, CT, United States 06484
Phone
203-937-6137
Fax
203-859-5095

Executives

Chairman of the Board, President
Anil Diwan
Chief Financial Officer
Meeta Vyas
Independent Director
Makarand Jawadekar
Independent Director
Theodore Rokita
Independent Director
Brian Zucker

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$16.8M
Revenue (TTM)
$0.00
Shares Outstanding
11.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.13
EPS
$-0.61
Book Value
$1.99
P/E Ratio
-2.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.